Sterling Wu

A phase 2, randomized dose‐finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis

A. Paller, K. Gallagher, J. Peppers, 2019, Journal of the American Academy of Dermatology.

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

S. Swindells, S. Oka, C. Orkin, 2020, Journal of acquired immune deficiency syndromes.

Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection

Sterling Wu, S. Snedecor, N. van de Velde, 2022, BMC Infectious Diseases.

Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection

Sterling Wu, S. Snedecor, N. van de Velde, 2020, BMC Infectious Diseases.

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

D. Kuritzkes, J. Schapiro, J. Polli, 2021, AIDS.

Post-Marketing Safety Evaluation of a Tetanus Toxoid, Reduced Diphtheria Toxoid and 3-Component Acellular Pertussis Vaccine Administered to a Cohort of Adolescents in a United States Health Maintenance Organization

E. Lewis, Ping Li, S. Black, 2010, The Pediatric infectious disease journal.

LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

Sterling Wu, C. Harrington, D. Margolis, 2020 .

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

E. Plimack, B. Melichar, B. Rini, 2023, Journal of Clinical Oncology.